Albert Bourla Leads Pfizer to $63.6B Triumph in 2024 – Record Growth, Bold Strategy, and a Sharpened Vision for 2025!

Pfizer Inc. reported robust financial results for the full year 2024, achieving total revenues of $63.6 billion, reflecting a 7% year-over-year operation...

February 04, 2025 | Tuesday | Company results
Mesoblast Advances U.S. Commercial Launch of Ryoncil® for Pediatric SR-aGvHD, with Key Milestones Ahead

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases,  provided an update on the progres...

January 31, 2025 | Friday | News
Kardigan Launches with $300 Million Series A to Transform Cardiovascular Disease Treatment

Company embarks on a vision to make cardiovascular disease curable, preventable, and no longer the leading cause of death worldwide Led by found...

January 13, 2025 | Monday | News
Andreessen Horowitz (a16z) and Eli Lilly Launch $500 Million Biotech Ecosystem Venture Fund to Drive Healthcare Innovation

Andreessen Horowitz (a16z) Bio + Health  announced a newly formed, first-of-its-kind venture capital fund to fuel broader innovation in human health...

January 13, 2025 | Monday | News
Former Humanigen CSO Dale Chappell Indicted for Insider Trading Scheme Avoiding $38M in Losses

An indictment unsealed on charged the former chief scientific officer of biopharmaceutical company Humanigen (0KB2.BE), opens new tab with engagi...

December 30, 2024 | Monday | News
Catalent’s $16.5 Billion Acquisition by Novo Holdings Sets the Stage for Transforming Global Healthcare

Catalent, Inc. (“Catalent”), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S...

December 19, 2024 | Thursday | News
BD Resolves SEC Investigation with $175 Million Settlement Related to Alaris™ System Disclosures

BD (Becton, Dickinson and Company) , a leading global medical technology company,  issued the following statement: BD has reached an agreement with...

December 17, 2024 | Tuesday | News
bluebird bio Announces 1-for-20 Reverse Stock Split to Regain Nasdaq Listing Compliance

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) announced that it will proceed with a 1-for-20 reverse stock sp...

December 09, 2024 | Monday | News
DANNCE.AI Secures $2.6M Pre-Seed Funding to Transform Neurological Care with AI-Powered Movement Analysis

DANNCE.AI raised $2.6 million in pre-seed funding led by LDV Capital, following initial investment from Glasswing Ventures, with participation from The L...

November 22, 2024 | Friday | News
CEO Adam Levy Announces Record-Breaking Q3 Revenue for NEXGEL with 141% Year-Over-Year Growth to $2.94 Million

NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hyd...

November 14, 2024 | Thursday | Company results
Lars Fruergaard Jørgensen Announces 21% Surge in Novo Nordisk’s Operating Profit, Driven by Strong Demand for Diabetes and Obesity Treatments

 Financial report for the period 1 January 2024 to 30 September 2024                      &nb...

November 06, 2024 | Wednesday | Company results
Bionomics Secures AUS$1M Milestone Payment from Carina Biotech for Progress in Australia’s Oncology Program

Bionomics , a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from s...

November 05, 2024 | Tuesday | News
Ate Therapeutics Grants 16,400 Restricted Stock Units to New Employees

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripot...

November 04, 2024 | Monday | News
Norman Schwartz Announces Bio-Rad’s Q3 Sales of $649.7 Million with 3.4% Currency-Neutral Growth, Driven by Clinical Diagnostics

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products,  announced financial r...

October 31, 2024 | Thursday | Company results

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close